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Background: Epidemiological studies have suggested that variants on adiponectin (ADIPOQ) and its receptor
ADIPOR1 (adiponectin receptor 1) are associated with colorectal cancer (CRC) risk; however, the results were
inconclusive. The aim of the study was to evaluate the associations between the variants on ADIPOQ and ADIPOR1
and the CRC risk with a hospital-based case-control study in the Chinese population along with meta-analysis of
available epidemiological studies.
Methods: With a hospital-based case-control study of 341 cases and 727 controls, the associations between the
common variants on ADIPOQ (rs266729, rs822395, rs2241766 and rs1501299) and ADIPOR1 (rs1342387 and rs12733285)
and CRC susceptibility were evaluated. Meta-analysis of the published epidemiological studies was performed to
investigate the associations between the variants and CRC risk.
Results: For the population study, we found that variant rs1342387 of ADIPOR1 was associated with a reduced
risk for CRC [adjusted odds ratio (OR) = 0.74, 95% confidential intervals (95% CI) = 0.57-0.97; CT/TT vs. CC]. The
meta-analysis also suggested a significant association for rs1342387 and CRC risk; the pooled OR was 0.79
(95% CI = 0.66-0.95) for the CT/TT carriers compared to CC homozygotes under the random-effects model (Q = 8.06,
df = 4, P = 0.089; I2 = 50.4%). The case-control study found no significant association for variants rs266729, rs822395,
rs2241766, and rs1501299 on ADIPOQ or variant rs12733285 on ADIPOR1 and CRC susceptibility, which were consistent
with results from the meta-analysis studies.
Conclusions: These data suggested that variant rs1342387 on ADIPOR1 may be a novel CRC susceptibility factor.
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unless otherwise stated.likely to confer an increased risk of colorectal cancer
(CRC) have drawn more attention [1]. Epidemiological
studies found that several markers for insulin resistance
and hyperinsulinemia, including high blood insulin, glu-
cose, IGF-1, and C-peptide levels, are associated with
the increased CRC risk [2]. Adiponectin (ADIPOQ), an
insulin sensitizer secreted principally by adipocytes, is
inversely associated with body fat, obesity, insulin resist-
ance through the stimulation of insulin secretion, incre-
ment of fatty acid combustion and energy consumption
[3]. Prospective studies demonstrated that an elevated
adiponectin level was associated with the reduced risk of
CRC in men [4], suggested that adiponectin and itss is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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development of CRC.
Two adiponectin receptors (ADIPOR1 and ADIPOR2)
mediate the biological activities of adiponectin in the ac-
tivation of AMP-activated protein kinase activities,
peroxisome proliferator-activated receptor-α and p38
mitogen-activated protein kinase, which lead to the
enhanced fatty-acid oxidation in skeletal muscle cells [5].
ADIPOR1 is abundantly expressed in skeletal muscle
cells, while ADIPOR2 is predominantly expressed in the
liver cells [6]. Interestingly, adiponectin receptors are also
found to be expressed in human malignant cells, includ-
ing colorectal cancer, breast cancer, and prostate cancer
etc., and they mediate the anticancer activities of adipo-
nectin in the cells. ADIPOQ gene deficient mice showed
an increased incidence of colon polyps in relative to wild-
type mice when they were fed with a high-fat diet [7].
ADIPOQ deficiency mice also show the enhanced colo-
rectal carcinogenesis and hepatocellular carcinoma for-
mation activities induced by azoxymethane [8]. It was
suggested that ADIPOR1 is more important than the
ADIPOR2 in the regulation of the anticancer activities of
ADIPOQ, as an increment in epithelial cell prolifera-
tion in ADIPOR1-deficient mice but not in ADIPOR2-
deficient mice was found [7].
Since there are potential protective effects of ADIPOQ
and ADIPOR1 against colorectal carcinogenesis, single
nucleotide polymorphisms (SNPs) on genes ADIPOQ
and ADIPOR1 may contribute to the susceptibility to
CRC. Kaklamani et al. firstly evaluated the associations
between the variants of ADIPOQ and ADIPOR1 with
CRC risk in a two-stage case-control study [9]. They
found a variant, rs266729 (C > G) on ADIPOQ, was asso-
ciated with a reduced risk of CRC [9]. However, subse-
quent studies performed in other populations did not find
such association [10-13]. Kaklamani et al. also found a sig-
nificant association with CRC risk for rs822396 (ADIPOQ),
rs822395 (ADIPOQ), and rs1342387 (ADIPOR1) in their
first-stage study; however, no significant association was
found for these variants in the second-stage study [9]. He
et al. found two variants (rs1342387 and rs12733285) on
ADIPOR1 were associated with CRC risk, but not for
rs266729 [12]. Liu et al. found no significant association
for the above mentioned variants, but they identified a
novel SNP, rs1063538, on ADIPOQ that may contribute
to CRC susceptibility [13]. Other widely evaluated loci
on ADIPOQ and their associations with the CRC risk
including the rs2241766, which leads to a synonymous
mutation of the amino acid for ADIPOQ protein, and
rs1501299 (+276 G > T); however, no conclusive results
found [9,12,13].
In the current study, we further evaluated the associa-
tions between the variants of ADIPOQ and ADIPOR1
and the colorectal cancer in a southeast Chinesepopulation. As inconsistent results were found for stud-
ies evaluated the associations between variants on ADI-
POQ or ADIPOR1 and CRC risk, we also performed the
meta-analysis studies of the published epidemiological
studies to systematically evaluate the associations be-




All the participants recruited in the current study have
been described previously [14]. In briefly, a total of 341
CRC patients and 727 controls with the qualified DNA
sample were included. The cases were patients who re-
ceived the clinic treatments between 2001 and 2003
(aged between 30 and 80 years old) at three hospitals
(Xi'nan Hospital, Xinqiao Hospital and Daping Hospital)
in Chongqing City, China. All the cases were from
Chongqing or the surrounding regions (including the
Sichuan, Yunnan, and Guizhou provinces in the southwest
of China) and histopathologically diagnosed with primary
CRC for the first time within the past six months. No pre-
treatment were performed at the time of recruitment for
the participants. The controls were recruited from the
Departments of General Surgery, Orthopedics, or Trauma
who received the clinic treatments for trauma, bone frac-
ture, appendicitis, arthritis, or varicose vein in the same
hospitals. The controls were matched with the cases by age
(±5 years), sex, and residence. The participants were re-
cruited following the guidelines of the Japan, Korea, and
China Colorectal Cancer Collaboration Group. The study
protocol was approved by the ethics committees of the
participating hospitals, including the “Ethics Committee
of Xi'nan Hospital”, the “Ethics Committee of Xinqiao
Hospital” and the “Ethics Committee of Daping Hospital”.
All participants have provided a written informed consent
and completed a structured questionnaire regarding their
basic characteristics as previously reported [14].
SNP selection and genotyping
Four most widely studied SNPs on ADIPOQ (including
rs2241766, rs266729, rs822395 and rs1501299) and two
on ADIPOR1 (including rs12733285 and rs1342387) were
selected to evaluate their associations with CRC risk.
Genomic DNA was extracted with the Promega DNA
Purification Wizard kit according to the manufacturer’s
instructions and was stored at -20°C until use. Geno-
typing of the selected SNPs was performed using the
Taqman-MGB probes for SNP allelic discrimination
with a 7900HT Fast Real-Time PCR System (Applied
Biosystems Incorporated, USA). All of the primers and
probes were designed with Primer Express v3.0 (Applied
Biosystems Incorporated, USA) and synthesized by the
Shanghai GeneCore BioTechnologies Co., Ltd (Additional
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using SDS software version 2.3 (Applied Biosystems
Incorporated, USA). 10% of samples were randomly se-
lected to assess the reproducibility of the genotyping re-
sults, resulting in a more than 99% concordance.
Meta-analysis of the associations between the selected
variants with CRC risk
To assess the associations between the selected SNPs of
ADIPOQ and ADIPOR1 with CRC risk, we performed a
comprehensive and systematic search of PubMed and
MEDLINE databases (updated to June, 2014), with the
terms of “adiponectin,” “ADIPOQ,” “adiponectin recep-
tor 1,” and “ADIPOR1” in combination with “colorectal
cancer,” “colon cancer,” or “rectal cancer.” The goal was
to identify studies that have evaluated the associations
between the selected variants on the two genes and CRC
risk. All the references from the identified studies were
checked to identify any missing studies. The identifiedFigure 1 Working flow chart for the systematic selection of the studiereports were thoroughly examined to exclude potential
studies with overlapping populations. For those studies
with overlapping samples, the one with the largest sample
size and/or provided the detailed information about the
genotype information for the participants was included in
the meta-analysis. Studies were included only if they had
evaluated the associations between the selected variants
and CRC risk and provided sufficient information about
the frequency of the genotypes in cases and controls.
When there were sub-group studies or multiple study
stages in the reports, they were considered as individual
studies. The eligibility studies included were case-control,
cohort, or cross-sectional studies that reported in the Eng-
lish language. The working flow chart for identification of
eligible studies is shown in Figure 1.
For each report, the following information was ex-
tracted: first author, publication year, study type, study
location, total number of cases and controls, and the
allele frequency of the participants.s for meta-analysis.
Table 1 Characteristics of the participants in the hospital
based case-control study
Characteristics Case (N = 341) Control (N = 727) P value
Age (years,±SD) 53.7 ± 13.0 51.6 ± 11.2 0.010
Sex
Male 184 (54.0%) 409 (56.3%) 0.481
Female 157 (46.0%) 318 (53.7%)
Smoke
No 216 (63.3%) 445 (61.2%) 0.503
Yes 125 (36.7%) 282 (38.8%)
Alcohol (>15 g/d)
No 252 (73.9%) 582 (80.1%) 0.023
Yes 89 (26.1%) 145 (19.9%)
Recruited Center
Xi’nan Hospital 165 (48.4%) 360 (49.5%) 0.545
Xinqiao Hospital 128 (40.5%) 282 (38.8%)
Daping Hospital 48 (11.1%) 85 (11.7%)
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Differences in demographic characteristics were evaluated
by the χ2 test (for categorical variables) and Student’s
t-test (for continuous variables). The Hardy-Weinberg
equilibrium was assessed by the χ2 test [one degree of
freedom (d.f)] [16]. The prevalence of the genotypes for
each variant was measured in cases and controls, and the
associations between ADIPOQ or ADIPOR1 genotypes
and risk of CRC were estimated by computing odds ratios
(ORs) and their corresponding 95% confidence intervals
(95% CIs). The common homozygotes were recognized as
references under the unconditional logistic regression stat-
istical model with or without adjustments for covariants
age, sex, drinking habit, and smoking status. The additive
and the dominant genetic models were used to evaluate
the associations between the variants and CRC risk. The
false discovery rate (FDR) test was also performed to ad-
just the P-values for the multiple testing of the selected
variants.
For the meta-analysis, the pooled OR and its 95% CI
for the dominant genetic effect model of the selected
variants were calculated using the standard inverse vari-
ance weighting method for the fixed-effects model and
the DerSimonian-Laird method for the random-effects
model. Heterogeneity between studies was assessed
using the Cochrane’s Q-test together with the I2 statistic.
Heterogeneity between the studies was considered sig-
nificant when P < 0.1 for the Q-test or the I2 value was
more than 25%. If significant heterogeneity between
studies was found, the overall pooled estimate under the
random-effects model rather than the fixed-effects
model was acceptable. Publication bias was graphically
represented by funnel plotting and was further assessed
by Egger’s linear regression test [17]. Sensitivity analyses
were conducted to evaluate the influence of individual
studies on overall estimates by sequential removal of
each individual study. Statistical analyses were accom-
plished using R Software and the SNPassoc and Meta
packages (http://www.r-project.org/).Results
Patient characteristics
The characteristics of the participants recruited are shown
in Table 1. The mean age of the CRC cases was slightly
greater than that for the control participants (P = 0.01,
Table 1). Consistent with previous reports [14,18], more
CRC patients had a higher daily average alcohol intake
(>15 g/day) than the controls (P = 0.023, Table 1). Other
potential confounders, including sex and smoking status,
were not significantly different between the cases and con-
trols (Table 1). No significant difference was also found for
the percentage of the cases and controls recruited from the
three hospitals (P = 0.545, Table 1).Results for genotyping
The genotyping results of the selected SNPs in the CRC
cases and controls are shown in Table 2. The overall call
rate for each SNP was > 96%, and none of the selected
SNPs was deviate from the Hardy-Weinberg equilibrium
test (P > 0.05, Table 2). Of the six genotyped SNPs, only
rs1342387 showed a significant association with CRC
risk (adjusted OR = 0.80, 95% CI = 0.60-1.06 for CT vs.
CC and adjusted OR = 0.59, 95% CI = 0.38-0.89 for TT
vs. CC; P-trend = 0.009). Under the dominant model, the
allele T carriers showed a significant decreased risk of
CRC (adjusted OR = 0.74, 95% CI = 0.57-0.97; P = 0.028)
in relative to the common CC carriers (Table 2). After
the multiple testing corrections with the FDR method,
the P value was 0.168 under the dominant genetic model
and the P-trend value was 0.054 for rs1342387. For variant
rs266729 of ADIPOQ, which may influence the circulating
adiponectin levels, there was no significant association
with CRC risk under any genetic model (Table 2). None of
the other SNPs (rs822395, rs2241766, and rs1501299 on
ADIPOQ or rs12733285 on ADIPOR1) was significantly
associated with CRC risk (Table 2).
Eligible studies for the meta-analysis
The working flow chart presented the selection process
and the reasons for study exclusion from the meta-
analysis studies (Figure 1). A total of 234 studies were
initially retrieved by the database search, and 220 were
excluded based on information in the titles and abstracts
of the reports. For the 14 remaining, two studies that
did not provide the detailed frequency data [19,20] and
another study reported by Yi et al. [21], with the same
Table 2 Summary data for correlation, call rate, and Hardy-Weinberg equilibrium test for each SNP on ADIPOQ
and ADIPOR1
SNP Genotype Cases (N %) Controls (N %) Crude OR (95% CI) Adjusted ORa (95% CI) P valuea P-trenda Call rate HWE-test
rs2241766 TT 153 (47.4) 374 (52.6) 1 1 0.137 96.91% 0.462
TG 141 (43.7) 278 (39.0) 1.24 (0.94-1.63) 1.26 (0.95-1.66) 0.109
GG 29 (9.0) 59 (8.3) 1.20 (0.74-1.95) 1.24 (0.76-2.02) 0.389
TG + GG 1.23 (0.95-1.60) 1.25 (0.96-1.64) 0.096
rs822395 AA 226 (69.5) 501 (71.7) 1 1 0.670 96.00% 0.529
AC 89 (27.4) 179 (25.6) 1.10 (0.82-1.49) 1.09 (0.81-1.47) 0.587
CC 10 (3.1) 19 (2.7) 1.17 (0.53-2.55) 1.07 (0.48-2.35) 0.870
AC + CC 1.11 (0.83-1.48) 1.09 (0.81-1.45) 0.582
rs266729 CC 164 (49.0) 378 (52.1) 1 1 0.219 99.63% 0.054
CG 152 (45.4) 305 (42.1) 1.15 (0.88-1.51) 1.18 (0.90-1.54) 0.233
GG 22 (5.7) 42 (5.8) 1.21 (0.70-2.09) 1.23 (0.71-2.13) 0.469
CG + GG 1.16 (0.89-1.50) 1.18 (0.91-1.54) 0.203
rs1501299 GG 197 (60.6) 420 (59.2) 1 1 0.512 96.81% 0.306
TG 110 (33.8) 244 (34.5) 0.96 (0.72-1.27) 0.95 (0.71-1.26) 0.708
TT 18 (5.5) 44 (6.2) 0.87 (0.49-1.55) 0.83 (0.46-1.48) 0.530
TG + TT 0.95 (0.72-1.24) 0.92 (0.70-1.21) 0.594
rs12733285 CC 289 (85.5) 614 (86.0) 1 1 0.848 98.59% 0.106
CT 47 (13.9) 93 (13.0) 1.07 (0.74-1.57) 1.03 (0.71-1.52) 0.846
TT 2 (0.6) 7 (1.0) 0.61 (0.13-2.94) 0.55 (0.11-2.69) 0.460
CT + TT 1.04 (0.70-1.53) 1.00 (0.69-1.45) 0.994
rs1342387 CC 159 (48.0) 289 (40.5) 1 1
CT 135 (40.8) 312 (43.8) 0.79 (0.59-1.04) 0.80 (0.60-1.06) 0.123
TT 37 (11.2) 112 (15.7) 0.60 (0.39-0.91) 0.59 (0.38-0.89) 0.013 0.009 97.84% 0.072
CT + TT 0.74 (0.57-0.96) 0.74 (0.57-0.97) 0.028
aAdjusted for age, sex, alcohol use, and smoking status.
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excluded. Thus, eleven case-control studies, along with
our current study, were included in our meta-analysis
(Additional file 1 Tables S2-S7) [9-13,22-26].
Results of the meta-analysis studies
The four included reports, with five individual studies
that recruited a total of 1,871 cases and 2,597 controls,
have evaluated the association between variant rs1342387Figure 2 Forest plot for the meta-analysis study between rs1342387and CRC risk (Additional file 1 Table S2) [9,12,13]. As
determined by the meta-analysis, rs1342387 was found to
be significantly associated with a reduced CRC risk, the
pooled OR was 0.79 (95% CI = 0.66-0.95, P = 0.011;
CT and TT vs. CC) under the random-effects model
(Figure 2). Significant heterogeneity between the studies
was found, as suggested by the I2 statistic and the Q-test
(I2 = 50.4%; Q = 8.06, df = 4, P = 0.089; Table 3). The
sensitivity analysis was performed by omitting one studyand CRC risk under the dominant model (CT/TT vs. CC).




(OR, 95% CI), p-value
Random-effects model
(OR, 95% CI), p-value
Q-value/df P value for
Q test
I2 P value of
Egger’s test
rs1342387 1871/2597 CC 1 1
CT 0.80 (0.70-0.92), 0.002 0.82 (0.67-1.00), 0.052 8.55/4 0.0733 53.2% 0.307
TT 0.71 (0.59-0.86), < 0.001 0.71 (0.59-0.86), < 0.001 3.28/4 0.5114 0% 0.351
CT + TT 0.77 (0.68-0.89), < 0.001 0.79 (0.66-0.95), 0.011 8.06/4 0.089 50.4% 0.209
rs266729 3635/4411 CC 1 1
CG 0.97 (0.79-1.19), 0.756 0.97 (0.77-1.22), 0.784 6.42/5 0.267 22.2% 0.253
GG 0.94 (0.84-1.05), 0.262 0.93 (0.78-1.10), 0.381 11.95/5 0.036 58.2% 0.288
CG + GG 0.95 (0.86-1.03), 0.221 0.93 (0.81-1.08), 0.354 14.45/6 0.025 58.5% 0.401
rs2241766 1519/2310 TT 1 1
TG 1.23 (1.08-1.40), 0.002 1.16 (0.92-1.46), 0.202 15.83/6 0.147 62.1% 0.120
GG 1.19 (0.92-1.53), 0.174 1.19 (0.91-1.56), 0.209 6.38/6 0.382 6.0% 0.670
TG + GG 1.22 (1.07-1.37), 0.002 1.18 (0.96-1.43), 0.108 12.93/6 0.044 53.6% 0.173
rs1501299 2749/4005 GG 1 1
TG 0.92 (0.82-1.02), 0.088 0.95 (0.82-1.05), 0.133 11.34/9 0.253 20.6% 0.083
TT 0.97 (0.81-1.18), 0.946 0.97 (0.81-1.18), 0.782 7.11/8 0.524 0% 0.530
TG + TT 0.92 (0.84-1.02), 0.131 0.93 (0.83-1.04), 0.205 10.49/9 0.312 14.2% 0.086
rs822395 1901/2639 AA 1 1
AC 1.01 (0.88-1.16), 0.898 1.00 (0.86-1.18), 0.963 5.38/4 0.250 25.7% 0.498
CC 0.92 (0.72-1.17), 0.497 0.92 (0.72-1.17), 0.502 3.04/4 0.551 0% 0.032
AC + CC 0.99 (0.87-1.13), 0.927 0.99 (0.87-1.13), 0.930 3.83/4 0.429 0% 0.793
rs12733285 1401/2139 CC 1 1
CT 0.86 (0.72-1.03), 0.092 0.86 (0.65-1.13), 0.277 6.81/3 0.0782 56.0% 0.841
TT 0.96 (0.69-1.33), 0.786 0.96 (0.69-1.33), 0.795 1.45/2 0.485 0% 0.958
CT + TT 0.87 (0.74-1.04), 0.108 0.87 (0.66-1.14), 0.304 7.12/3 0.068 57.8% 0.813
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remained studies repeatedly. After excluding the study
performed by He et al. [12], which contributed mostly to
the heterogeneity between the studies, a consistent sig-
nificant reduced risk for CRC was found with the pooled
OR was 0.84 (95% CI = 0.73-0.98; I2 = 0%; Q = 2.51, df = 3,
P = 0.47) for the CT and TT carriers in relative to CC car-
riers. No significant publication bias was found (Egger’s
test, P = 0.209). Thus, the results suggested that rs1342387
may contribute to the susceptibility of CRC, which were
consistent with the results of our population study.
rs266729 was firstly identified as a potential suscepti-
bility locus on ADIPOQ for CRC (9). From the literature
search, we identified six studies with seven subgroup
studies that recruited a total of 3,635 cases and 4,411
controls (Additional file 1 Table S3) have evaluated the
association between the rs266729 and colorectal cancer
risk [9-13]. The meta-analysis showed that rs266729 did
not associated with CRC risk (pooled OR = 0.93, 95%
CI = 0.81-1.08, P = 0.354; CG/GG vs. CC) under the
random effects model, and significant heterogeneity be-
tween the studies was found (I2 = 58.5%; Q = 14.45, df = 6,P = 0.025; Figure 3 and Table 3). After excluding the pion-
eer study conducted by Kaklamani et al. [9], which contrib-
uted mostly of the heterogeneity between the studies,
the pooled OR was 1.00 (95% CI = 0.91-1.11; I2 = 0.7%;
Q = 4.03, df = 4, P = 0.402) under the random-effects
model. No significant publication bias was detected for the
meta-analysis studies. The data indicated that rs266729
may be not a susceptibility factor for colorectal cancer.
The association of CRC risk and the other four loci
were evaluated in six studies for rs2241766 (Additional
file 1 Table S4), eight studies for rs1501299 (Additional
file 1 Table S5), four studies for rs822395 (Additional file 1
Table S6), and three studies for rs12733285 (Additional
file 1 Table S7). In our meta-analysis studies, we found
no significant association between the loci and CRC
risk (Table 3). The sensitivity analyses were performed to
identify any individual study that significantly affects the
overall estimates in the meta-analysis studies. Through se-
quential removal of individual study that has determined
the association between the variant and CRC risk for
rs822395 or rs12733285, the overall estimates for either
locus did not significantly changed. However, when the
Figure 3 Forest plot for the association between rs266729 with CRC under the dominant model (CG/GG vs. CC).
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which contributed mostly to the heterogeneity between
the studies for rs2241766, the pooled OR was 1.26 (95%
CI = 1.11-1.42; Q = 4.35, df = 5, P = 0.500, I2 = 0%) for the
TG/GG carriers compared to TT carriers. For rs1501299,
sensitivity analysis indicated that the study conducted by
Tisilidiset al. [22] contributed mostly to the heterogeneity
between the studies. The pooled OR was 0.89 (95%
CI = 0.80-0.99; Q = 5.55, df = 8, p = 0.698; I2 = 0%) for
TG/GG carriers compared to TT carriers after the study
was excluded in the meta-analysis study. No significant
publication bias was found, as determined by Egger’s test
for all the meta-analysis studies (Table 3).
Discussion
From the hospital-based case-control study, we found
that rs1342387 on ADIPOR1 was significantly associated
with a reduced CRC risk; however, no significant associ-
ation with the CRC risk for variants rs266729, rs2241766,
rs822395, rs1501299, and rs12733285 was found. As de-
termined by the meta-analysis of published epidemio-
logical studies, only variant rs1342387 was significantly
associated with the reduced CRC susceptibility, whereas
limited data supported the associations between the other
loci and CRC susceptibility. As the consistent results were
found for the selected variants between hospital based
case-control studies and the meta-analysis studies, which
suggested that rs1342387 is associated with a reduced risk
for colorectal cancer. Our results appeared to provide a
genetic relationship between obesity, hyperinsulinemia,
and/or insulin resistance and the risk of CRC.
Variant rs1342387 was associated with a reduced CRC
risk in the Chinese population, which is consistent with
the study conducted by He et al. [12] and the first-stage
study of Kaklamani et al. [9]. Although the P value for
multiple testing with the FDR method suggested a statis-
tically non-significant association between the rs1342387
and CRC risk, which could be due to the high linkage
disequilibrium (LD) between the variants, the results
from the meta-analysis studies provided stronger evi-
dence that the allele T carriers were associated with asignificant reduced risk of CRC in relative to CC homo-
zygotes. rs1342387 is located in intron 4 (+5843 C > T)
of the ADIPOR1 gene, a locus associated with body size
measurements, such as weight, height, waist and hip cir-
cumference, sagittal diameter, and body mass index [27].
Another study, performed in the Amish population,
found that allele T for variant rs1342387 was associated
with a reduced risk for type 2 diabetes, although the
possibility that other functional loci in high linkage-
disequilibrium with rs1342387 may account for this as-
sociation could not be excluded [29]. Crimmins et al.
summarized the association between the variants of
ADIPOR1 and ADIPOR2 with insulin resistance and type
2 diabetes, and they found that only rs1342387 was sig-
nificantly associated with the reduced risk for insulin re-
sistance [30]. Since insulin resistance and type 2 diabetes
may lead to susceptibility to various types of cancer, the
variant may be a susceptibility factor for CRC and other
obesity-related cancers.
The variant rs266729 has been reported to be associ-
ated with higher circulating adiponectin levels [31,32],
higher plasma total antioxidant status (32), lower plasma
oxidized-LDL levels [33], and reduced risk for type 2
diabetes [34]. Other studies, however, did not find an as-
sociation for the variant with blood lipids [35], blood
pressure [35], or with coronary heart disease risk [36].
There are no significant allelic specific effects of pro-
moter activity for rs266729 alone [37], and rs266729
may act together with other loci to regulate the activity
of the adiponectin promoter [38]. In their first-stage
study, Kaklamani et al. reported a significant association
for the locus and CRC risk in a population of Ashkenazi
origin. In their second-stage study, a significant associ-
ation between the variant and CRC risk in a population
of mixed origins was also noticed [9]. However, subse-
quent studies found no such association, except for one
study conducted by He et al. have reported that the vari-
ant was associated with colon cancer susceptibility but
not rectal cancer [12]. Meta-analysis of the epidemio-
logical studies suggested that the locus does not con-
tribute to CRC susceptibility. The original study may
Ou et al. BMC Medical Genetics  (2014) 15:137 Page 8 of 10represent a chance observation. However, the possibil-
ity that the association observed by Kaklamani et al.
[9] is attributed to the population-specific effects for
rs266729 on CRC risk cannot be excluded, as the sub-
sequent studies were conducted in other countries or
races. There is also a possibility that the variant acts to-
gether with other variants to influence the CRC risk,
and the genetic background may influence the associ-
ation of the variant and CRC risk. Thus, more studies
with fine-mapping methods, are warranted to address these
questions.
For the other four variants, we found no significant as-
sociation with CRC risk in our hospital based case-
control population study, which was consistent with the
results of the meta-analysis studies. For variant rs2241766,
which is located on exon 2 of ADIPOQ, the G to T allelic
change leads to a synonymous variation of the amino acid
(Gly to Gly). The meta-analysis study found no significant
association between the variant and CRC risk; however,
the sensitivity study suggested that the results may
be affected by the heterogeneity between the studies.
rs1501299 is located on intron 2 (+276 G > T) of ADIPOQ
and the meta-analysis conducted by Xu et al. found a de-
creased CRC risk for GT and TT carriers compared to GG
carriers; however, only four studies were included [39].
For the current meta-analysis study, based on eight stud-
ies, suggested that the locus is not associated with CRC
risk; however, when the study performed by Tisilidis et al.
[22], which contributed mostly to the heterogeneity be-
tween the studies was excluded, the pooled estimate sug-
gested that the variant may be a protective factor for CRC.
Whether rs2241766 and rs1501299 are associated with the
CRC susceptibility should be determined with more stud-
ies of relatively larger sample size. Variant rs822395 is lo-
cated on intron 1 of ADIPOQ, and rs12733285 is located
on intron 1 of ADIPOR1. Neither variant showed a signifi-
cant association with CRC risk in our population study or
in the meta-analysis studies.
We acknowledged that there were several limitations
for the current study. Firstly, the investigation was a
hospital based case-control study, which is more prone
to selection bias of the participants. The age of the
control subjects was slightly younger than that for the
CRC cases, and the CRC risk for the controls was diffi-
cult to determine. Secondly, the relatively small sample
size may lead to a lower statistical power to detect the
association between rs266729 and other variants with
CRC risk. Lastly, the underlying mechanisms for the
association between rs1342387 and CRC risk need to
be elucidated.
Conclusions
In conclusion, variant rs1342387 of ADIPOR1 may
contribute to CRC susceptibility. Results from ourpopulation study and meta-analysis suggest that vari-
ants rs266729, rs822395, rs2241766, and rs1501299
of ADIPOQ and variant rs12733285 of ADIPOR1 may
not contribute to CRC susceptibility. However, more
investigations with larger sample sizes are warranted
to validate these results and the underlying mecha-
nisms are also need to be elucidated.Additional file
Additional file 1: Table S1. Information on primers and probes used
for genotyping of the six variants. Table S2. Studies included in the
meta-analysis for the association between rs1342387 and CRC. Table S3.
Studies included in the meta-analysis for the association between rs266729
and CRC. Table S4. Studies included in the meta-analysis for the association
between rs2241766 and CRC. Table S5. Studies included in the meta-analysis
for the association between rs1501299 and CRC. Table S6. Studies
included in the meta-analysis for the association between rs822395 and CRC.
Table S7. Studies included in the meta-analysis for the association between
rs12733285 and CRC.Competing interests
The author’s declare that they have no competing interests.Authors’ contributions
PC, JC and HW conceived and designed the experiments; YO, ZZ and CL
performed the experiments; YO, PC and JG analyzed the data; JL and KT
contributed to the reagents, materials and related analysis tools; YO, PC and
HW wrote the paper. All author’s read and approved the final manuscript.Acknowledgments
This study was supported by grants from the Ministry of Science and
Technology of China (2012BAK01B00 and 2014AA020524), the National
Nature Science Foundation (81125020, 81302507, 31200569 and 81302809),
the Key Research Program(KSZD-EW-Z-021 and KSZD-EW-Z-019)of the
Chinese Academy of Sciences, the Science and Technology Commission
of Shanghai Municipality (12431900500, 14391901800), and the Food Safety Re-
search Center and Key Laboratory of Food Safety Research of INS, SIBS, CAS. And
partially supported by General Programs (81273156,30771841 and 30700676)
and a Major International (Regional) Joint Research Projects (30320140461)
from the National Natural Science Foundation of China (NSFC), and by a Grant-in
Aid for Scientific Research on Special Priority Areas of Cancer from the Ministry of
Education, Culture, Sports, Science and Technology of Japan (12670383). The fun-
ders had no role in study design, data collection and analysis, decision to publish,
or preparation of the manuscript.
Author details
1Key Laboratory of Food Safety Research, Institute for Nutritional Sciences,
Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences,
University of Chinese Academy of Sciences, Shanghai, 200031, P. R China.
2Medical Department, The General Hospital of Navy, Beijing, 100037, P. R
China. 3Toxicology Institute, Key Lab of Medical Protection for Electromagnetic
Radiation, Ministry of Education of China, College of Preventive Medicine; Third
Military Medical University, Chongqing, 400038, P. R. China. 4Department of
Environment Health, College of Preventive Medicine; Third Military Medical
University, Chongqing, 400038, P. R. China. 5Division of Epidemiology and
Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan. 6Department
of Military Hygiene, Faculty of Naval Medicine, Second Military Medical University,
Shanghai, 200433, P. R. China. 7Key Laboratory of Food Safety Risk Assessment,
Ministry of Health, Beijing, 100021, P. R. China. 8School of Life Science and
Technology, ShanghaiTech University, Shanghai, 200031, P. R. China.
Received: 25 July 2014 Accepted: 11 December 2014
Ou et al. BMC Medical Genetics  (2014) 15:137 Page 9 of 10References
1. Siddiqui AA: Metabolic syndrome and its association with colorectal
cancer: a review. Am J Med Sci 2011, 341:227–231.
2. Tsai CJ, Giovannucci EL: Hyperinsulinemia, Insulin Resistance, Vitamin D,
and Colorectal Cancer Among Whites and African Americans. Dig Dis Sci
2012, 57:2497–503.
3. Esteve E, Ricart W, Fernandez-Real JM: Adipocytokines and insulin
resistance: the possible role of lipocalin-2, retinol binding protein-4,
and adiponectin. Diabetes Care 2009, 32(Suppl 2):S362–367.
4. Wei EK, Giovannucci E, Fuchs CS, Willett WC, Mantzoros CS: Low plasma
adiponectin levels and risk of colorectal cancer in men: a prospective
study. J Natl Cancer Inst 2005, 97:1688–1694.
5. Yoon MJ, Lee GY, Chung JJ, Ahn YH, Hong SH, Kim JB: Adiponectin
increases fatty acid oxidation in skeletal muscle cells by sequential
activation of AMP-activated protein kinase, p38 mitogen-activated
protein kinase, and peroxisome proliferator-activated receptor alpha.
Diabetes 2006, 55:2562–2570.
6. Rasmussen MS, Lihn AS, Pedersen SB, Bruun JM, Rasmussen M,
Richelsen B: Adiponectin receptors in human adipose tissue: effects
of obesity, weight loss, and fat depots. Obesity (Silver Spring) 2006,
14:28–35.
7. Fujisawa T, Endo H, Tomimoto A, Sugiyama M, Takahashi H, Saito S, Inamori M,
Nakajima N, Watanabe M, Kubota N, Yamauchi T, Kadowaki T, Wada K,
Nakagama H, Nakajima A: Adiponectin suppresses colorectal carcinogenesis
under the high-fat diet condition. Gut 2008, 57:1531–1538.
8. Nishihara T, Baba M, Matsuda M, Inoue M, Nishizawa Y, Fukuhara A, Araki H,
Kihara S, Funahashi T, Tamura S, Hayashi N, Iishi H, Shimomura I:
Adiponectin deficiency enhances colorectal carcinogenesis and liver
tumor formation induced by azoxymethane in mice. World J Gastroenterol
2008, 14:6473–6480.
9. Kaklamani VG, Wisinski KB, Sadim M, Gulden C, Do A, Offit K, Baron JA,
Ahsan H, Mantzoros C, Pasche B: Variants of the adiponectin (ADIPOQ)
and adiponectin receptor 1 (ADIPOR1) genes and colorectal cancer risk.
JAMA 2008, 300:1523–1531.
10. Pechlivanis S, Bermejo JL, Pardini B, Naccarati A, Vodickova L, Novotny J,
Hemminki K, Vodicka P, Forsti A: Genetic variation in adipokine genes and
risk of colorectal cancer. Eur J Endocrinol 2009, 160:933–940.
11. Gornick MC, Rennert G, Moreno V, Gruber SB: Adiponectin gene and risk
of colorectal cancer. Br J Cancer 2011, 105:562–564.
12. He B, Pan Y, Zhang Y, Bao Q, Chen L, Nie Z, Gu L, Xu Y, Wang S: Effects
of genetic variations in the adiponectin pathway genes on the risk of
colorectal cancer in the Chinese population. BMC Med Genet 2011,
12:94.
13. Liu L, Zhong R, Wei S, Yin JY, Xiang H, Zou L, Chen W, Chen JG, Zheng XW,
Huang LJ, Zhu BB, Chen Q, Duan SY, Rui R, Yang BF, Sun JW, Xie DS, Xu YH,
Miao XP, Nie SF: Interactions between Genetic Variants in the Adiponectin,
Adiponectin Receptor 1 and Environmental Factors on the Risk of Colorectal
Cancer. PLoS One 2011, 6:e27301.
14. Li M, Zhou Y, Chen P, Yang H, Yuan X, Tajima K, Cao J, Wang H: Genetic
variants on chromosome 8q24 and colorectal neoplasia risk: a case-
control study in China and a meta-analysis of the published literature.
PLoS One 2011, 6:e18251.
15. Wu X, Chen P, Ou Y, Liu J, Li C, Wang H, Qiang F: Association of variants
on ADIPOQ and AdipoR1 and the prognosis of gastric cancer patients
after gastrectomy treatment. Mol Biol Rep 2014, [Epub ahead of print].
16. Loibl S, von Minckwitz G, Schwedler K, Schmidt KA, Hoper D, Kaufmann M,
Costa SD: Mitomycin C, 5-fluorouracil and folinic acid (Mi-Fu-Fo) as
salvage chemotherapy in breast cancer patients with liver metastases
and impaired hepatic function: a phase II study. Anticancer Drugs 2004,
15:719–724.
17. Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta-analysis
detected by a simple, graphical test. BMJ 1997, 315:629–634.
18. Yang H, Zhou Y, Zhou Z, Liu J, Yuan X, Matsuo K, Takezaki T, Tajima K, Cao J:
A novel polymorphism rs1329149 of CYP2E1 and a known polymorphism
rs671 of ALDH2 of alcohol metabolizing enzymes are associated with
colorectal cancer in a southwestern Chinese population. Cancer Epidemiol
Biomarkers Prev 2009, 18:2522–2527.
19. Carvajal-Carmona LG, Spain S, Kerr D, Houlston R, Cazier JB, Tomlinson
I: Common variation at the adiponectin locus is not associated with
colorectal cancer risk in the UK. Hum Mol Genet 2009,
18:1889–1892.20. Al Khaldi RM, Al Mulla F, Al Awadhi S, Kapila K, Mojiminiyi OA: Associations
of single nucleotide polymorphisms in the adiponectin gene with
adiponectin levels and cardio-metabolic risk factors in patients with
cancer. Dis Markers 2011, 30:197–212.
21. Yi N, Kaklamani VG, Pasche B: Bayesian analysis of genetic interactions in
case-control studies, with application to adiponectin genes and colorectal
cancer risk. Ann Hum Genet 2011, 75:90–104.
22. Tsilidis KK, Helzlsouer KJ, Smith MW, Grinberg V, Hoffman-Bolton J, Clipp
SL, Visvanathan K, Platz EA: Association of common polymorphisms in
IL10, and in other genes related to inflammatory response and
obesity with colorectal cancer. Cancer Causes Control 2009,
20:1739–1751.
23. Partida-Perez M, de la Luz A-MM, Peregrina-Sandoval J, Macias-Gomez N,
Moreno-Ortiz J, Leal-Ugarte E, Cardenas-Meza M, Centeno-Flores M,
Maciel-Gutierrez V, Cabrales E, Cervantes-Ortiz S, Gutiérrez-Angulo M:
Association of LEP and ADIPOQ common variants with colorectal
cancer in Mexican patients. Cancer Biomark 2010, 7:117–121.
24. Al-Harithy RN, Al-Zahrani MH: The adiponectin gene, ADIPOQ, and genetic
susceptibility to colon cancer. Oncol Lett 2012, 3:176–180.
25. Keku TO, Vidal A, Oliver S, Hoyo C, Hall IJ, Omofoye O, McDoom M, Worley K,
Galanko J, Sandler RS, Millikan R: Genetic variants in IGF-I, IGF-II, IGFBP-3, and
adiponectin genes and colon cancer risk in African Americans and Whites.
Cancer Causes Control 2012, 23:1127–38.
26. Hu X, Yuan P, Yan J, Feng F, Li X, Liu W, Yang Y: Gene Polymorphisms of
+45 T > G, -866G > A, and Ala54Thr on the Risk of Colorectal Cancer: A
Matched Case-Control Study. PLoS One 2013, 8:e67275.
27. Qi L, Doria A, Giorgi E, Hu FB: Variations in adiponectin receptor genes
and susceptibility to type 2 diabetes in women: a tagging-single
nucleotide polymorphism haplotype analysis. Diabetes 2007,
56:1586–91.
28. Siitonen N, Pulkkinen L, Mager U, Lindstrom J, Eriksson JG, Valle TT,
Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Tuomilehto J,
Laakso M, Uusitupa M: Association of sequence variations in the gene
encoding adiponectin receptor 1 (ADIPOR1) with body size and insulin
levels. The Finnish Diabetes Prevention Study. Diabetologia 2006,
49:1795–1805.
29. Damcott CM, Ott SH, Pollin TI, Reinhart LJ, Wang J, O'Connell JR, Mitchell BD,
Shuldiner AR: Genetic variation in adiponectin receptor 1 and adiponectin
receptor 2 is associated with type 2 diabetes in the Old Order Amish.
Diabetes 2005, 54:2245–2250.
30. Crimmins NA, Martin LJ: Polymorphisms in adiponectin receptor
genes ADIPOR1 and ADIPOR2 and insulin resistance. Obes Rev 2007,
8:419–423.
31. Ong KL, Li M, Tso AW, Xu A, Cherny SS, Sham PC, Tse HF, Lam TH, Cheung
BM, Lam KS: Association of genetic variants in the adiponectin gene with
adiponectin level and hypertension in Hong Kong Chinese. Eur J
Endocrinol 2010, 163:251–257.
32. Persson J, Lindberg K, Gustafsson TP, Eriksson P, Paulsson-Berne G,
Lundman P: Low plasma adiponectin concentration is associated
with myocardial infarction in young individuals. J Intern Med 2010,
268:194–205.
33. Prior SL, Gable DR, Cooper JA, Bain SC, Hurel SJ, Humphries SE, Stephens JW:
Association between the adiponectin promoter rs266729 gene variant and
oxidative stress in patients with diabetes mellitus. Eur Heart J 2009,
30:1263–1269.
34. Han LY, Wu QH, Jiao ML, Hao YH, Liang LB, Gao LJ, Legge DG, Quan H,
Zhao MM, Ning N, Kang Z, Sun H: Associations between single-nucleotide
polymorphisms (+45 T > G, +276G > T, -11377C > G, -11391G > A) of
adiponectin gene and type 2 diabetes mellitus: a systematic review
and meta-analysis. Diabetologia 2011, 54(9):2303–2314.
35. Zhao T, Zhao J: Genetic effects of adiponectin on blood lipids and blood
pressure. Clin Endocrinol (Oxf ) 2011, 74:214–222.
36. Pischon T, Pai JK, Manson JE, Hu FB, Rexrode KM, Hunter D, Rimm EB:
Single nucleotide polymorphisms at the adiponectin locus and risk of
coronary heart disease in men and women. Obesity (Silver Spring) 2007,
15:2051–2060.
37. Kyriakou T, Collins LJ, Spencer-Jones NJ, Malcolm C, Wang X, Snieder H,
Swaminathan R, Burling KA, Hart DJ, Spector TD, O'Dell SD: Adiponectin
gene ADIPOQ SNP associations with serum adiponectin in two female
populations and effects of SNPs on promoter activity. J Hum Genet 2008,
53:718–727.
Ou et al. BMC Medical Genetics  (2014) 15:137 Page 10 of 1038. Laumen H, Saningong AD, Heid IM, Hess J, Herder C, Claussnitzer M,
Baumert J, Lamina C, Rathmann W, Sedlmeier EM, Klopp N, Thorand B,
Wichmann HE, Illig T, Hauner H: Functional characterization of promoter
variants of the adiponectin gene complemented by epidemiological
data. Diabetes 2009, 58:984–991.
39. Xu Y, He B, Pan Y, Gu L, Nie Z, Chen L, Li R, Gao T, Wang S: The roles of
ADIPOQ genetic variations in cancer risk: evidence from published
studies. Mol Biol Rep 2013, 40:1135–1144.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
